Colin Maclaine Fadzen

Massachusetts Institute Of Technology

$142,380

Attributed

$142,380

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $49.5K · FY2017–19

$50K$37.5K$25K$12.5K$0

'17

'18

'19

Funding mix

By agency

NIH$142,380 · 1

By mechanism

F30$142,380 · 1

Top collaborators

No co-investigators on record.

Most similar at Massachusetts Institute Of Technology

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Dosage”

Richard Scranton · Lyndra Therapeutics, Inc.$12,106,230
Melissa Allard · Albany Molecular Research, Inc.$8,788,340
Patrick Boen · Lyndra Therapeutics, Inc.$8,679,033
Warren David Lo · Virginia Polytechnic Inst And St Univ$7,604,467
Erin Rooney Riggs · Broad Institute, Inc.$6,471,349
Montserrat C Anguera · University Of Pennsylvania$6,121,298

Research focus

DosageDose10 Year OldCysteineAreaAge-YearsBindingAffectAntisense OligonucleotidesCell MembraneCell ModelCell NucleusCellsBaseCessation Of LifeChemistryChildBoysCardiomyopathiesChimera OrganismClinical EfficacyCommunitiesCostDuchenne Muscular Dystrophy

Grant awards (4)

Chemically Modified Peptide Agents for Next-Generation Conjugate Therapies to Treat Duchenne Muscular Dystrophy$43,812

F30 · FY2019 · HD · contact PI

Chemically Modified Peptide Agents for Next-Generation Conjugate Therapies to Treat Duchenne Muscular Dystrophy$49,524

F30 · FY2018 · HD · contact PI

Chemically Modified Peptide Agents for Next-Generation Conjugate Therapies to Treat Duchenne Muscular Dystrophy$38,883

F30 · FY2017 · HD · contact PI

Chemically Modified Peptide Agents for Next-Generation Conjugate Therapies to Treat Duchenne Muscular Dystrophy$10,161

F30 · FY2017 · HD · contact PI